FGP
MDLN

Freestone Grove Partners’s Medline Inc MDLN Stock Holding History

Freestone Grove Partners’s Portfolio MDLN Stock Details MDLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,089,014
Closed -$48.5M – 1394
2026
Q1 		$48.5M Buy
1,089,014
+582,514
+115% +$25.7M 0.34% 95
2025
Q4 		$21.3M Buy
+506,500
New +$21.4M 0.15% 200

Other funds holding MDLN

CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
HFCIX
H&F Corporate Investors X San Francisco, California $2.8B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Freestone Grove Partners's MDLN Position: Q2 2026 in Review

Freestone Grove Partners sold out of Medline Inc (MDLN) in Q2 2026, closing a stake of 1,089,014 shares — an estimated $48.5M sold.

Freestone Grove Partners first reported a position in MDLN in Q4 2025 and held it in 2 quarters. The position peaked at $48.5M in Q1 2026. 407 funds tracked by Wall St. Rank hold MDLN as of Q2 2026.

  • Freestone Grove Partners reported no remaining Medline Inc position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 1,089,014 Medline Inc shares in Q2 2026, an estimated $48.5M.
  • Freestone Grove Partners first reported a position in Medline Inc in Q4 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Medline Inc position peaked at $48.5M in Q1 2026.
  • 407 funds tracked by Wall St. Rank held Medline Inc as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.